Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study—authors’ response - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Journal of Antimicrobial Chemotherapy Année : 2020

Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study—authors’ response

Anne-Geneviève Marcelin
Fichier non déposé

Dates et versions

hal-03338886 , version 1 (09-09-2021)

Identifiants

Citer

Christine Katlama, Lambert Assoumou, Marc-Antoine Valantin, Cathia Soulié, Esteban Martinez, et al.. Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study—authors’ response. Journal of Antimicrobial Chemotherapy, 2020, 75 (12), pp.3699-3700. ⟨10.1093/jac/dkaa341⟩. ⟨hal-03338886⟩
39 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More